Whether its a bull or bear market, TrendingWallStreet has you covered. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get exclusive access to our free stock reports.
China New Borun Corporation (NYSE: BORN) shares closed up 20.79 percent on Monday with nearly 2.3 million shares traded. The stock traded in between $1.78 and $2.47 yesterday. The company had no significant news and plans to release its unaudited financial results for the third quarter 2013 on November 13, 2013, after the market closes.
Get more information on China New Borun Corporation and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/EGY
TheDirectory.com, Inc. (OTC: SEEK) shares closed down 11.11 percent on about 130 million shares traded on Monday. The stock traded in a range of 0.0039 - 0.0051 yesterday. TheDirectory.com, Inc. operates as a diversified local Internet search company. The company owns and operates a network of locally targeted, category specific search destinations through its local business search engine, TheDirectory.com.
Get more information on TheDirectory.com, Inc. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/SEEK
First Titan Corp. (OTCBB: FTTN) shares finally closed down 19.73 percent on Monday on a little over 600,000 shares traded. The stock traded in between 0.64 and 1.07 a share yesterday. FTTN, an oil and gas energy company seeking continued growth of a diversified oil and gas portfolio is negotiating with BioFuels Power Corp., an industry-accomplished company that possesses the technology to increase the financial returns of FTTN’s natural gas resource holdings and acquisition targets.
Get more information on First Titan Corp. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/FTTN
Sanofi (NASDAQ: GCVRZ) shares closed down 10.39 percent on Monday and traded in between 0.64 and 0.76 a share. The stock traded about 6.8 million shares yesterday. Recently U.S. regulatory officials have raised concerns about "multiple serious and potentially fatal safety issues" in patients given Sanofi's new multiple sclerosis drug Lemtrada. The Food and Drug Administration (FDA) staff said in a report prepared ahead of a Nov. 13 advisory panel that the risks might be too great to justify approval in the world's biggest pharmaceutical market, unless the drug showed "substantial clinical benefit."
Get more information on Sanofi and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/GCVRZ
Disclosure: TrendingWallStreet.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.